![Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome | BMC Cancer | Full Text Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2407-13-413/MediaObjects/12885_2012_Article_4043_Fig1_HTML.jpg)
Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome | BMC Cancer | Full Text
![Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study | BMJ Open Ophthalmology Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study | BMJ Open Ophthalmology](https://bmjophth.bmj.com/content/bmjophth/5/1/e000377/F1.medium.gif)
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study | BMJ Open Ophthalmology
![PDF) Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study PDF) Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study](https://i1.rgstatic.net/publication/332311826_Effectiveness_and_safety_of_intravitreal_aflibercept_in_patients_with_wet_age-related_macular_degeneration_treated_in_routine_clinical_practices_across_France_12-month_outcomes_of_the_RAINBOW_study/links/5cad4295458515cd2b0d332c/largepreview.png)